Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer

References

• Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2020;126(10):2225–2249. doi:10.1002/cncr.32802
   PubMed Web of Science ®Google Scholar
• Drouillard A, Manfredi S, Lepage C, Bouvier A-M. [Epidemiology of pancreatic cancer]. Bull Cancer. 2018;105(1):63–69. French. doi:10.1016/j.bulcan.2017.11.004
   PubMed Web of Science ®Google Scholar
• Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22(2):199–207. doi:10.1634/theoncologist.2016-0214
   PubMed Web of Science ®Google Scholar
• Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499–1506. doi:10.1182/blood-2017-03-743211
   PubMed Web of Science ®Google Scholar
• Sgouros J, Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of Phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol (Madr). 2008. doi:10.1080/02841860701687267
   Web of Science ®Google Scholar
• Kruger S, Haas M, Burkl C, et al. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - a retrospective cohort study. Thromb Res. 2017;157:9–15. doi:10.1016/j.thromres.2017.06.021
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656. doi:10.1200/JCO.2014.59.7351
   PubMed Web of Science ®Google Scholar
• Cao J, Fu Z, Gao L, et al. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma. World J Surg Oncol. 2017;1–8. doi:10.1186/s12957-017-1104-9
   PubMed Web of Science ®Google Scholar
• Kulic A, Cvetkovic Z, Libek V. Primary hyperfibrinolysis as the presenting sign of prostate cancer: a case report. Vojnosanit Pregl. 2016;73(9):877–880. doi:10.2298/VSP150525076K
   PubMed Web of Science ®Google Scholar
• Jafri MA, Cohen JV, Much MA, Petrylak DP, Podoltsev NA, Patient With A. Pancytopenia, intractable epistaxis, and metastatic prostate cancer: how correct diagnosis of primary hyperfibrinolysis helps to stop the bleeding. Clin Genitourin Cancer. 2016;14(5):e545–e548. doi:10.1016/j.clgc.2016.05.002
   PubMed Web of Science ®Google Scholar
• Naina HVK, Patnaik MM, Ali UA, Chen D, Ashrani AA. Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. J Clin Oncol. 2010;28(11):e167–e168. doi:10.1200/JCO.2009.25.2502
   PubMed Web of Science ®Google Scholar
• Baluka D, Urbanek T, Lekstan A, et al. The role of the tissue plasminogen activator as a prognostic and differentiation factor in patients with pancreatic cancer and chronic pancreatitis. J Physiol Pharmacol. 2016;67(1):93–101.
   PubMed Web of Science ®Google Scholar
• Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system. Clin Cancer Res. 2014;20(6):1477–1488. doi:10.1158/1078-0432.CCR-13-2311
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Kwaan HC. Components of the plasminogen-plasmin system as biologic markers for cancer. Adv Exp Med Biol. 2015;867:145–156.
   PubMed Web of Science ®Google Scholar
• Chen Q, Fei J, Wu L, et al. Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. Oncol Lett. 2011;2(4):693–699. doi:10.3892/ol.2011.302
   PubMed Web of Science ®Google Scholar
• Rubina KA, Sysoeva VY, Zagorujko EI, et al. Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas. Arch Dermatol Res. 2017;309(6):433–442. doi:10.1007/s00403-017-1738-z
   PubMed Web of Science ®Google Scholar
• Yang SF, Hsieh YS, Lin CL, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta. 2005;354(1–2):91–99. doi:10.1016/j.cccn.2004.11.011
   PubMed Web of Science ®Google Scholar
• Urban P, Vuaroqueaux V, Labuhn M, et al. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol. 2006;24(26):4245–4253. doi:10.1200/JCO.2005.05.1912
   PubMed Web of Science ®Google Scholar
• Halamkova J, Kiss I, Pavlovsky Z, et al. Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients. Neoplasma. 2011;58(5):377–385. doi:10.4149/neo_2011_05_377
   PubMed Web of Science ®Google Scholar
• Liu Q, Li W, Yang S, Liu Z. High expression of uPA related to p38MAPK in esophageal cancer indicates poor prognosis. Onco Targets Ther. 2018;11:8427–8434. doi:10.2147/OTT.S181701
   PubMed Web of Science ®Google Scholar
• Ma J, Qi G, Xu J, et al. Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis. Oncol Lett. 2017;14(6):7288–7296. doi:10.3892/ol.2017.7136
   PubMed Web of Science ®Google Scholar
• Wang X, Wang N, Li H, et al. Up-regulation of PAI-1 and down-regulation of uPA are involved in suppression of invasiveness and motility of hepatocellular carcinoma cells by a natural compound berberine. Int J Mol Sci. 2016;17(4):577. doi:10.3390/ijms17040577
   PubMed Web of Science ®Google Scholar
• Kumano M, Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol. 2009;27(2):180–186. doi:10.1016/j.urolonc.2008.01.012
   PubMed Web of Science ®Google Scholar
• Taubert H, Wurl P, Greither T, et al. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer. 2010;102(4):731–737. doi:10.1038/sj.bjc.6605520
   PubMed Web of Science ®Google Scholar
• Pavon MA, Arroyo-Solera I, Cespedes MV, Casanova I, Leon X, Mangues R. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. Oncotarget. 2016;7(35):57351–57366. doi:10.18632/oncotarget.10344
   PubMedGoogle Scholar
• Nielsen A, Scarlett CJ, Samra JS, et al. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol. 2005;20:256–263. doi:10.1111/j.1400-1746.2004.03531.x
   PubMed Web of Science ®Google Scholar
• Shin SJ, Kim KO, Kim MK, et al. Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer. Japan J Clin Oncol. 2005;35(6):342–348. doi:10.1093/jjco/hyi094
   PubMed Web of Science ®Google Scholar
• Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 1999;18(32):4554–4563. doi:10.1038/sj.onc.1202833
   PubMed Web of Science ®Google Scholar
• Harvey SR, Hurd TC, Markus G, et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res. 2003;9(13):4935–4943.
   PubMed Web of Science ®Google Scholar
• Gibbs JF, Schlieman M, Singh P, et al. A pilot study of urokinase-type plasminogen activator (uPA) overexpression in the brush cytology of patients with malignant pancreatic or biliary strictures. HPB Surg. 2009;2009:1–5. doi:10.1155/2009/805971
   Google Scholar
• Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol. 1993;88(11):1928–1933.
   PubMed Web of Science ®Google Scholar
• Boss EA, Massuger LFAG, Thomas CMG, et al. Clinical value of components of the plasminogen activation system in ovarian cyst fluid. Anticancer Res. 2002;22(1A):275–282.
   PubMed Web of Science ®Google Scholar
• Shim BS, Kang BH, Hong YK, et al. The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth. Biochem Biophys Res Commun. 2005;327(4):1155–1162. doi:10.1016/j.bbrc.2004.12.126
   PubMed Web of Science ®Google Scholar
• Grebenchtchikov N, Maguire TM, Riisbro R, et al. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep. 2005;14(1):235–239.
   PubMed Web of Science ®Google Scholar
• Sciacca FL, Ciusani E, Silvani A, et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res. 2004;10(4):1312–1317. doi:10.1158/1078-0432.ccr-03-0198
   PubMed Web of Science ®Google Scholar
• De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 1998;58(10):2234–2239.
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Sierko E, Zacharski LR, Rózanska-Kudelska M, Zimnoch L. Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer. Semin Thromb Hemost. 2003;29(3):317–320. doi:10.1055/s-2003-40970
   PubMed Web of Science ®Google Scholar
• Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol. 2009;29(8):1151–1155. doi:10.1161/ATVBAHA.108.179655
   PubMed Web of Science ®Google Scholar
• Marignol L, Robson T, McCarthy HO, et al. The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate? J Gene Med. 2008;10(9):1032–1038. doi:10.1002/jgm.1221
   PubMed Web of Science ®Google Scholar
• Sanz L, Vizoso F, Vérez P, et al. Prognostic significance of tissue-type plasminogen activator (tPA) content in gastric cancer and surrounding mucosa. Int J Biol Markers. 2002;17(3):169–176. doi:10.1177/172460080201700305
   PubMed Web of Science ®Google Scholar
• Neudecker J, Neudecker BA, Raue W, Stern R, Schwenk W. Hyaluronan levels during laparoscopic versus open colonic resections. Surg Endosc. 2008;22(3):660–663. doi:10.1007/s00464-007-9455-x
   PubMed Web of Science ®Google Scholar
• Chappuis PO, Dieterich B, Sciretta V, et al. Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol. 2001;19(10):2731–2738. doi:10.1200/JCO.2001.19.10.2731
   PubMed Web of Science ®Google Scholar
• Corte MD, Vérez P, Rodríguez JC, et al. Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance. Breast Cancer Res Treat. 2005;90(1):33–40. doi:10.1007/s10549-004-2624-x
   PubMed Web of Science ®Google Scholar
• Diaz VM, Planaguma J, Thomson TM, Reventos J, Paciucci R. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology. 2002;122(3):806–819. doi:10.1053/gast.2002.31885
   PubMed Web of Science ®Google Scholar
• Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004;53(7):993–1000. doi:10.1136/gut.2003.026831
   PubMed Web of Science ®Google Scholar
• Nielsen VG, Matika RW, Ley MLB, et al. Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer. Blood Coagul Fibrinolysis. 2014;25(3):248–253. doi:10.1097/MBC.0000000000000040
   PubMed Web of Science ®Google Scholar
• Gao F, Li J, Quan S, et al. Risk factors and treatment for hemorrhage after pancreaticoduodenectomy: a case series of 423 patients. Biomed Res Int. 2016;2016:2815693. doi:10.1155/2016/2815693
   PubMed Web of Science ®Google Scholar
• Uramoto H, Shimokawa H, Tanaka F. Postoperative bleeding after surgery in patients with lung cancer. Anticancer Res. 2014;34(2):981–984.
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol. 2012;2012:564259. doi:10.1155/2012/564259
   PubMedGoogle Scholar
• Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost. 2013;39(4):382–391. doi:10.1055/s-0033-1338127
   PubMed Web of Science ®Google Scholar
• Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res. 2009;148:43–66. doi:10.1007/978-0-387-79962-9_4
   PubMedGoogle Scholar
• Houard X, Monnot C, Dive V, Corvol P, Pagano M. Vascular smooth muscle cells efficiently activate a new proteinase cascade involving plasminogen and fibronectin. J Cell Biochem. 2003;88(6):1188–1201. doi:10.1002/jcb.10460
   PubMed Web of Science ®Google Scholar
• Diao D, Cheng Y, Song Y, Zhang H, Zhou Z, Dang C. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer. BMC Cancer. 2017;17(1):56. doi:10.1186/s12885-016-3043-1
   PubMed Web of Science ®Google Scholar
• Mego M, Zuo Z, Gao H, et al. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost. 2015;113(3):593–598. doi:10.1160/TH14-07-0597
   PubMed Web of Science ®Google Scholar
• Mego M, Karaba M, Minarik G, et al. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients. Breast J. 2015;21(2):155–160. doi:10.1111/tbj.12388
   PubMed Web of Science ®Google Scholar
• Stender MT, Larsen AC, Sall M, Thorlacius-Ussing O. D-dimer predicts prognosis and non-resectability in patients with pancreatic cancer: a prospective cohort study. Blood Coagul Fibrinolysis. 2016;27(5):597–601. doi:10.1097/MBC.0000000000000559
   PubMed Web of Science ®Google Scholar
• Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis. 1993;14(12):2575–2579. doi:10.1093/carcin/14.12.2575
   PubMed Web of Science ®Google Scholar
• Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem. 1994;269(33):21198–21203.
   PubMed Web of Science ®Google Scholar
• Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994;269(33):21191–21197.
   PubMed Web of Science ®Google Scholar
• Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22(2–3):205–222. doi:10.1023/a:1023099415940
   PubMed Web of Science ®Google Scholar
• Gorantla B, Asuthkar S, Rao JS, Patel J, Gondi CS. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res. 2011;9(4):377–389. doi:10.1158/1541-7786.MCR-10-0452
   PubMed Web of Science ®Google Scholar
• DiPardo BJ, Winograd P, Court CM, Tomlinson JS. Pancreatic cancer circulating tumor cells: applications for personalized oncology. Expert Rev Mol Diagn. 2018;18(9):809–820. doi:10.1080/14737159.2018.1511429
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007;62(2):126–136. doi:10.1016/j.critrevonc.2007.01.001
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Barbui T. Thrombocytosis and thrombosis. Hematology Am Soc Hematol Educ Program. 2007;2007:363–370. doi:10.1182/asheducation-2007.1.363
   Google Scholar
• Hwang SG, Kim KM, Cheong JH, et al. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 2012;38(7):562–567. doi:10.1016/j.ejso.2012.04.009
   PubMed Web of Science ®Google Scholar
• Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9(9):1826–1830. doi:10.1183/09031936.96.09091826
   PubMed Web of Science ®Google Scholar
• Cravioto-Villanueva A, Luna-Perez P, Gutierrez-de la Barrera M, et al. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res. 2012;43(4):305–311. doi:10.1016/j.arcmed.2012.06.008
   PubMed Web of Science ®Google Scholar
• Zhu J-F, Cai L, Zhang X-W, et al. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases. Chin J Cancer. 2014;33(2):96–104. doi:10.5732/cjc.012.10307
   PubMedGoogle Scholar
• Yamamoto M, Kurokawa Y, Miyazaki Y, et al. Usefulness of preoperative plasma fibrinogen versus other prognostic markers for predicting gastric cancer recurrence. World J Surg. 2016;40(8):1904–1909. doi:10.1007/s00268-016-3474-5
   PubMed Web of Science ®Google Scholar
• Fan S, Guan Y, Zhao G, An G. Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma. Thorac Cancer. 2018;9(1):146–151. doi:10.1111/1759-7714.12556
   PubMed Web of Science ®Google Scholar
• Man Y-N, Wang Y-N, Hao J, et al. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. Int J Gynecol Cancer. 2015;25(1):24–32. doi:10.1097/IGC.0000000000000303
   PubMed Web of Science ®Google Scholar
• Erdem S, Amasyali AS, Aytac O, Onem K, Issever H, Sanli O. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics. Urol Oncol. 2014;32(7):1031–1040. doi:10.1016/j.urolonc.2014.03.013
   PubMed Web of Science ®Google Scholar
• Wang H, Gao J, Bai M, et al. The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer. Platelets. 2014;25(5):382–387. doi:10.3109/09537104.2013.827782
   PubMed Web of Science ®Google Scholar
• Liu P, Zhu Y, Liu L. Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma. Onco Targets Ther. 2015;8:1335–1340. doi:10.2147/OTT.S82329
   PubMed Web of Science ®Google Scholar
• Guo Q, Zhang B, Dong X, et al. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas. 2009;38(3):e75–e79. doi:10.1097/MPA.0b013e3181987d86
   PubMed Web of Science ®Google Scholar
• Kurahara H, Maemura K, Mataki Y, et al. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Pancreatology. 2015;15(6):688–693. doi:10.1016/j.pan.2015.09.015
   PubMed Web of Science ®Google Scholar
• Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 2000;6(1):100–102. doi:10.1038/71429
   PubMed Web of Science ®Google Scholar
• Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005;31(4):381–392. doi:10.1055/s-2005-916671
   PubMed Web of Science ®Google Scholar
• Jackson SP. Arterial thrombosis–insidious, unpredictable and deadly. Nat Med. 2011;17(11):1423–1436. doi:10.1038/nm.2515
   PubMed Web of Science ®Google Scholar
• Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–134. doi:10.1038/nrc3004
   PubMed Web of Science ®Google Scholar
• Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988;81(4):1012–1019. doi:10.1172/JCI113411
   PubMed Web of Science ®Google Scholar
• Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104(21):9024–9028. doi:10.1073/pnas.0700625104
   PubMed Web of Science ®Google Scholar
• Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost. 2009;7(10):1713–1717. doi:10.1111/j.1538-7836.2009.03559.x
   PubMed Web of Science ®Google Scholar
• Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998;95(16):9325–9330. doi:10.1073/pnas.95.16.9325
   PubMed Web of Science ®Google Scholar
• Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz). 2006;54(2):75–84. doi:10.1007/s00005-006-0010-6
   PubMed Web of Science ®Google Scholar
• Wei M, Tai G, Gao Y, et al. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem. 2004;279(28):29202–29210. doi:10.1074/jbc.M312951200
   PubMed Web of Science ®Google Scholar
• McCarty OJ, Mousa SA, Bray PF, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood. 2000;96(5):1789–1797. doi:10.1182/blood.V96.5.1789
   PubMed Web of Science ®Google Scholar
• Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28(3):403–412. doi:10.1161/ATVBAHA.107.150474
   PubMed Web of Science ®Google Scholar
• Da Q, Behymer M, Correa JI, Vijayan KV, Cruz MA. Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. Blood. 2014;123(17):2715–2721. doi:10.1182/blood-2013-10-530428
   PubMed Web of Science ®Google Scholar
• Hong S-H, Misek DE, Wang H, et al. Identification of a specific vimentin isoform that induces an antibody response in pancreatic cancer. Biomark Insights. 2006;1:175–183. doi:10.1177/117727190600100006
   PubMedGoogle Scholar
• Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178–185. doi:10.1182/blood-2004-06-2272
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Degen JL. Fibrinogen and tumor cell metastasis. Haemostasis. 2001;31 Suppl 1(Suppl 1):11–15.
   PubMedGoogle Scholar
• Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002;62(23):6966–6972.
   PubMed Web of Science ®Google Scholar
• Tsakadze NL, Zhao Z, D’Souza SE. Interactions of intercellular adhesion molecule-1 with fibrinogen. Trends Cardiovasc Med. 2002;12(3):101–108. doi:10.1016/S1050-1738(01)00157-8
   PubMed Web of Science ®Google Scholar
• Roland CL, Dineen SP, Toombs JE, et al. Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. Exp Biol Med (Maywood). 2010;235(2):263–270. doi:10.1258/ebm.2009.009215
   PubMed Web of Science ®Google Scholar
• Tempia-Caliera AA, Horvath LZ, Zimmermann A, et al. Adhesion molecules in human pancreatic cancer. J Surg Oncol. 2002;79(2):93–100. doi:10.1002/jso.10053
   PubMed Web of Science ®Google Scholar
• Shimoyama S, Gansauge F, Gansauge S, Kaminishi M, Beger HG. Basal expression and cytokine induction of intercellular adhesion molecule-1 in human pancreatic cancer cell lines. J Exp Clin Cancer Res. 1999;18(1):107–110.
   PubMed Web of Science ®Google Scholar
• Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol. 2004;25(9):489–495. doi:10.1016/j.it.2004.07.003
   PubMed Web of Science ®Google Scholar
• Lam FW, Vijayan KV, Rumbaut RE. Platelets and their interactions with other immune cells. Compr Physiol. 2015;5(3):1265–1280. doi:10.1002/cphy.c140074
   PubMed Web of Science ®Google Scholar
• Kopp H-G, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69(19):7775–7783. doi:10.1158/0008-5472.CAN-09-2123
   PubMed Web of Science ®Google Scholar
• Placke T, Örgel M, Schaller M, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–448. doi:10.1158/0008-5472.CAN-11-1872
   PubMed Web of Science ®Google Scholar
• Placke T, Kopp H-G, Salih HR. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun. 2011;3(4):374–382. doi:10.1159/000323936
   PubMed Web of Science ®Google Scholar
• Rachidi S, Metelli A, Riesenberg B, et al. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol. 2017;2(11):eaai7911. doi:10.1126/sciimmunol.aai7911
   PubMed Web of Science ®Google Scholar
• Maugeri N, Campana L, Gavina M, et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost. 2014;12(12):2074–2088. doi:10.1111/jth.12710
   PubMed Web of Science ®Google Scholar
• Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123(8):3446–3458. doi:10.1172/JCI67484
   PubMed Web of Science ®Google Scholar
• Boone BA, Orlichenko L, Schapiro NE, et al. The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther. 2015;22(6):326–334. doi:10.1038/cgt.2015.21
   PubMed Web of Science ®Google Scholar
• Ahrens I, Chen Y-C, Topcic D, et al. HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi. Thromb Haemost. 2015;114(11):994–1003. doi:10.1160/TH14-12-1073
   PubMedGoogle Scholar
• Chung HW, Lim J-B, Jang S, Lee KJ, Park KH, Song SY. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci. 2012;103(9):1714–1721. doi:10.1111/j.1349-7006.2012.02358.x
   PubMed Web of Science ®Google Scholar
• Wittwer C, Boeck S, Heinemann V, et al. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer. 2013;133(11):2619–2630. doi:10.1002/ijc.28294
   PubMed Web of Science ®Google Scholar
• Zheng S, Shen J, Jiao Y, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci. 2009;100(5):859–865. doi:10.1111/j.1349-7006.2009.01115.x
   PubMed Web of Science ®Google Scholar
• Mastoraki A, Mastoraki S, Schizas D, et al. Facing the challenge of venous thromboembolism prevention in patients undergoing major abdominal surgical procedures for gastrointestinal cancer. World J Gastrointest Oncol. 2018;10(10):328–335. doi:10.4251/wjgo.v10.i10.328
   PubMed Web of Science ®Google Scholar
• Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104(2):397–401. doi:10.1182/blood-2004-02-0434
   PubMed Web of Science ®Google Scholar
• Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003;90(09):549–554. doi:10.1160/TH03-02-0102
   PubMedGoogle Scholar
• Zhang W, Dang S, Hong T, et al. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood. 2012;120(14):2889–2898. doi:10.1182/blood-2012-04-425207
   PubMed Web of Science ®Google Scholar
• Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003;100(24):14205–14210. doi:10.1073/pnas.2234372100
   PubMed Web of Science ®Google Scholar
• Erpenbeck L, Nieswandt B, Schön M, Pozgajova M, Schön MP. Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. J Invest Dermatol. 2010;130(2):576–586. doi:10.1038/jid.2009.278
   PubMed Web of Science ®Google Scholar
• Lavergne M, Janus-Bell E, Schaff M, Gachet C, Mangin PH. Platelet integrins in tumor metastasis: do they represent a therapeutic target? Cancers (Basel). 2017;9(10):133. doi:10.3390/cancers9100133
   PubMed Web of Science ®Google Scholar
• Qi C-L, Wei B, Ye J, et al. P-selectin-mediated platelet adhesion promotes the metastasis of murine melanoma cells. PLoS One. 2014;9(3):e91320. doi:10.1371/journal.pone.0091320
   PubMed Web of Science ®Google Scholar
• Qi C, Wei B, Zhou W, et al. P-selectin-mediated platelet adhesion promotes tumor growth. Oncotarget. 2015;6(9):6584–6596. doi:10.18632/oncotarget.3164
   PubMed Web of Science ®Google Scholar
• Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131(16):1777–1789.
   PubMed Web of Science ®Google Scholar
• Zelenay S, van der Veen AG, Böttcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162(6):1257–1270. doi:10.1016/j.cell.2015.08.015
   PubMed Web of Science ®Google Scholar
• Alsubaie H, Leggett C, Lambert P, et al. Diagnosis of VTE postdischarge for major abdominal and pelvic oncologic surgery: implications for a change in practice. Can J Surg. 2015;58(5):305–311. doi:10.1503/cjs.012314
   PubMed Web of Science ®Google Scholar
• Cui G, Wang X, Yao W, Li H. Incidence of postoperative venous thromboembolism after laparoscopic versus open colorectal cancer surgery: a meta-analysis. Surg Laparosc Endosc Percutan Tech. 2013;23(2):128–134. doi:10.1097/SLE.0b013e3182827cef
   PubMed Web of Science ®Google Scholar
• Cheung HY, Chung CC, Yau KK, et al. Risk of deep vein thrombosis following laparoscopic rectosigmoid cancer resection in chinese patients. Asian J Surg. 2008;31(2):63–68. doi:10.1016/S1015-9584(08)60060-3
   PubMed Web of Science ®Google Scholar
• Gil-Bernabé AM, Lucotti S, Muschel RJ. Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol. 2013;162(4):433–441. doi:10.1111/bjh.12381
   PubMed Web of Science ®Google Scholar
• Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26(1):47–57. doi:10.1093/annonc/mdu225
   PubMed Web of Science ®Google Scholar
• Jiang M-J, Dai -J-J, Gu D-N, Huang Q, Tian L. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta. 2016;1866(2):163–176. doi:10.1016/j.bbcan.2016.08.002
   PubMed Web of Science ®Google Scholar
• Streicher SA, Yu H, Lu L, Kidd MS, Risch HA. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1254–1263. doi:10.1158/1055-9965.EPI-13-1284
   PubMed Web of Science ®Google Scholar
• Risch HA, Lu L, Streicher SA, et al. Aspirin use and reduced risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(1):68–74. doi:10.1158/1055-9965.EPI-16-0508
   PubMed Web of Science ®Google Scholar
• Cui X-J, He Q, Zhang J-M, Fan H-J, Wen Z-F, Qin Y-R. High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. Pancreas. 2014;43(1):135–140. doi:10.1097/MPA.0b013e3182a8d41f
   PubMed Web of Science ®Google Scholar
• Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605–1609. doi:10.1001/jama.1995.03520440059037
   PubMed Web of Science ®Google Scholar
• Yue W, Yang CS, DiPaola RS, Tan X-L. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila). 2014;7(4):388–397. doi:10.1158/1940-6207.CAPR-13-0337
   PubMed Web of Science ®Google Scholar
• Yue W, Zheng X, Lin Y, et al. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget. 2015;6(25):21208–21224. doi:10.18632/oncotarget.4126
   PubMedGoogle Scholar
• Mezouar S, Darbousset R, Dignat-George F, Panicot-Dubois L, Dubois C. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer. 2015;136(2):462–475. doi:10.1002/ijc.28997
   PubMed Web of Science ®Google Scholar
• Mitrugno A, Sylman JL, Ngo ATP, et al. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. Am J Physiol Cell Physiol. 2017;312(2):C176–C189. doi:10.1152/ajpcell.00196.2016
   PubMed Web of Science ®Google Scholar
• Chen H, Lan X, Liu M, Zhou B, Wang B, Chen P. Direct TGF-β1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity. Cell Biol Int. 2013;37(5):478–484. doi:10.1002/cbin.10067
   PubMed Web of Science ®Google Scholar
• Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet (London, England). 1992;339(8807):1476. doi:10.1016/0140-6736(92)92064-m
   PubMed Web of Science ®Google Scholar
• Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112(6):853–862. doi:10.1172/JCI18882
   PubMed Web of Science ®Google Scholar
• Klerk CPW, Smorenburg SM, Otten H-M, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130–2135. doi:10.1200/JCO.2005.03.134
   PubMed Web of Science ®Google Scholar
• Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost. 2004;92(09):627–633. doi:10.1160/TH04-02-0069
   PubMedGoogle Scholar
• Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res. 2007;120(Suppl):S107–s111. doi:10.1016/S0049-3848(07)70138-X
   PubMedGoogle Scholar
• Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98(6):3352–3357. doi:10.1073/pnas.061615598
   PubMed Web of Science ®Google Scholar
• Yoshitomi Y, Nakanishi H, Kusano Y, et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 2004;207(2):165–174. doi:10.1016/j.canlet.2003.11.037
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Ettelaie C, Echrish H, et al. Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagul Fibrinolysis. 2010;21(5):452–458. doi:10.1097/MBC.0b013e328338dc49
   PubMed Web of Science ®Google Scholar
• Sudha T, Yalcin M, Lin H-Y, et al. Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett. 2014;350(1–2):25–33. doi:10.1016/j.canlet.2014.04.016
   PubMed Web of Science ®Google Scholar
• Sudha T, Phillips P, Kanaan C, Linhardt RJ, Borsig L, Mousa SA. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model. Clin Exp Metastasis. 2012;29(5):431–439. doi:10.1007/s10585-012-9461-9
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949. doi:10.1016/S1470-2045(09)70232-3
   PubMed Web of Science ®Google Scholar
• von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RM, Lersch C. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost. 2007;98(08):434–439. doi:10.1160/TH07-01-0004
   PubMedGoogle Scholar
• Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol. 2007;95(6):507–512. doi:10.1002/jso.20728
   PubMed Web of Science ®Google Scholar
• Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33(18):2028–2034. doi:10.1200/JCO.2014.55.1481
   PubMed Web of Science ®Google Scholar
• Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a Phase 3 clinical trial. Mayo Clin Proc. 2006;81(6):758–767. doi:10.4065/81.6.758
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12(12):CD008500. doi:10.1002/14651858.CD008500.pub4
   PubMedGoogle Scholar